DANIELLE HAMILL: Open Payments
NPI 1679973119 · BLACKFOOT, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$986 in 50 payments from 11 companies in 2025. Trend: 2023 $330 · 2024 $495 · 2025 $986
Food & beverage: $986
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 16 | $236 |
| Otsuka America Pharmaceutical, Inc. | 7 | $156 |
| Vanda Pharmaceuticals Inc. | 5 | $124 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $110 |
| Alkermes, Inc. | 4 | $77 |
| ABBVIE INC. | 4 | $74 |
| Neurocrine BioSciences, Inc. | 3 | $63 |
| Axsome Therapeutics, Inc. | 2 | $53 |
| E.R. Squibb & Sons, L.L.C. | 3 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
Products named: AUSTEDO XR, FANAPT, CAPLYTA, UZEDY, ABILIFY ASIMTUFII, VRAYLAR, REXULTI, INGREZZA.
Industry payments across ID — which companies pay providers there.
